Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free ATXI Stock Alerts

Avenue Therapeutics (ATXI) Competitors

Avenue Therapeutics logo
$0.30 -0.02 (-6.25%)
As of 09:46 AM Eastern
Compare

ATXI vs. RDHL, ALZN, REVB, ALBT, and GRI

Should you buy Avenue Therapeutics stock or one of its competitors? MarketBeat compares Avenue Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avenue Therapeutics include Redhill Biopharma (RDHL), Alzamend Neuro (ALZN), Revelation Biosciences (REVB), Avalon GloboCare (ALBT), and GRI Bio (GRI). These companies are all part of the "pharmaceutical products" industry.

How does Avenue Therapeutics compare to Redhill Biopharma?

Redhill Biopharma (NASDAQ:RDHL) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Redhill Biopharma has higher revenue and earnings than Avenue Therapeutics. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Redhill Biopharma$290K14.14-$430K$1.05 thousand0.00
Avenue TherapeuticsN/AN/A-$10.38M-$0.53N/A

Redhill Biopharma's return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Redhill BiopharmaN/A N/A N/A
Avenue Therapeutics N/A -471.57%-296.50%

In the previous week, Redhill Biopharma had 4 more articles in the media than Avenue Therapeutics. MarketBeat recorded 4 mentions for Redhill Biopharma and 0 mentions for Avenue Therapeutics. Redhill Biopharma's average media sentiment score of 0.37 beat Avenue Therapeutics' score of 0.00 indicating that Redhill Biopharma is being referred to more favorably in the media.

Company Overall Sentiment
Redhill Biopharma Neutral
Avenue Therapeutics Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Redhill Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Redhill Biopharma has a beta of 4.98, suggesting that its stock price is 398% more volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.21, suggesting that its stock price is 121% less volatile than the broader market.

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by company insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Redhill Biopharma beats Avenue Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Avenue Therapeutics compare to Alzamend Neuro?

Avenue Therapeutics (NASDAQ:ATXI) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Alzamend Neuro's return on equity of -177.52% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Avenue TherapeuticsN/A -471.57% -296.50%
Alzamend Neuro N/A -177.52%-140.41%

In the previous week, Alzamend Neuro had 2 more articles in the media than Avenue Therapeutics. MarketBeat recorded 2 mentions for Alzamend Neuro and 0 mentions for Avenue Therapeutics. Alzamend Neuro's average media sentiment score of 0.93 beat Avenue Therapeutics' score of 0.00 indicating that Alzamend Neuro is being referred to more favorably in the news media.

Company Overall Sentiment
Avenue Therapeutics Neutral
Alzamend Neuro Positive

17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by company insiders. Comparatively, 1.4% of Alzamend Neuro shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Avenue Therapeutics has a beta of -0.21, indicating that its stock price is 121% less volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market.

Alzamend Neuro has a consensus price target of $28.00, indicating a potential upside of 2,185.71%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than Avenue Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Alzamend Neuro
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Alzamend Neuro is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avenue TherapeuticsN/AN/A-$10.38M-$0.53N/A
Alzamend NeuroN/AN/A-$4.51M-$2.16N/A

Summary

Alzamend Neuro beats Avenue Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Avenue Therapeutics compare to Revelation Biosciences?

Avenue Therapeutics (NASDAQ:ATXI) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Avenue Therapeutics has a beta of -0.21, suggesting that its share price is 121% less volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market.

Revelation Biosciences' return on equity of -107.65% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Avenue TherapeuticsN/A -471.57% -296.50%
Revelation Biosciences N/A -107.65%-87.98%

In the previous week, Revelation Biosciences had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for Revelation Biosciences and 0 mentions for Avenue Therapeutics. Revelation Biosciences' average media sentiment score of 1.89 beat Avenue Therapeutics' score of 0.00 indicating that Revelation Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Avenue Therapeutics Neutral
Revelation Biosciences Very Positive

17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by insiders. Comparatively, 4.8% of Revelation Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avenue TherapeuticsN/AN/A-$10.38M-$0.53N/A
Revelation BiosciencesN/AN/A-$8.91M-$39.48N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Revelation Biosciences beats Avenue Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Avenue Therapeutics compare to Avalon GloboCare?

Avalon GloboCare (NASDAQ:ALBT) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Avalon GloboCare has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.21, suggesting that its stock price is 121% less volatile than the broader market.

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avalon GloboCareN/AN/A-$18.26M-$3.51N/A
Avenue TherapeuticsN/AN/A-$10.38M-$0.53N/A

In the previous week, Avalon GloboCare had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for Avalon GloboCare and 0 mentions for Avenue Therapeutics. Avalon GloboCare's average media sentiment score of 1.87 beat Avenue Therapeutics' score of 0.00 indicating that Avalon GloboCare is being referred to more favorably in the media.

Company Overall Sentiment
Avalon GloboCare Very Positive
Avenue Therapeutics Neutral

Avalon GloboCare's return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Avalon GloboCareN/A N/A -74.36%
Avenue Therapeutics N/A -471.57%-296.50%

1.4% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 24.2% of Avalon GloboCare shares are owned by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avalon GloboCare
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Avalon GloboCare beats Avenue Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Avenue Therapeutics compare to GRI Bio?

GRI Bio (NASDAQ:GRI) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Avenue Therapeutics is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GRI BioN/AN/A-$11.96M-$74.16N/A
Avenue TherapeuticsN/AN/A-$10.38M-$0.53N/A

GRI Bio has a beta of -1.17, meaning that its stock price is 217% less volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.21, meaning that its stock price is 121% less volatile than the broader market.

In the previous week, GRI Bio had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for GRI Bio and 0 mentions for Avenue Therapeutics. GRI Bio's average media sentiment score of 1.87 beat Avenue Therapeutics' score of 0.00 indicating that GRI Bio is being referred to more favorably in the media.

Company Overall Sentiment
GRI Bio Very Positive
Avenue Therapeutics Neutral

34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 8.7% of GRI Bio shares are owned by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

GRI Bio's return on equity of -199.52% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
GRI BioN/A -199.52% -143.23%
Avenue Therapeutics N/A -471.57%-296.50%

GRI Bio presently has a consensus target price of $32.00, indicating a potential upside of 1,307.21%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts plainly believe GRI Bio is more favorable than Avenue Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GRI Bio
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

GRI Bio beats Avenue Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Avenue Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATXI vs. The Competition

Export
MetricAvenue TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$988K$960.50M$6.50B$12.36B
Dividend YieldN/A4.84%2.67%5.67%
P/E Ratio0.021.4323.9924.69
Price / SalesN/A125.05538.03166.93
Price / CashN/A20.0627.4837.92
Price / Book0.168.0110.476.82
Net Income-$10.38M-$4.88M$3.56B$337.45M
7 Day Performance-3.23%3.69%1.21%2.49%
1 Month PerformanceN/A2.56%2.14%4.37%
1 Year Performance44.09%49.45%26.24%32.80%

Avenue Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATXI
Avenue Therapeutics
N/A$0.30
-6.3%		N/A+53.7%$988KN/A0.024
RDHL
Redhill Biopharma
1.0174 of 5 stars		$0.91
+3.4%		N/A-53.7%$4.73M$290K0.00210
ALZN
Alzamend Neuro
3.8291 of 5 stars		$1.20
+3.0%		$28.00
+2,243.1%		-62.7%$4.48MN/AN/A4
REVB
Revelation Biosciences
1.4011 of 5 stars		$1.04
+0.2%		N/A-89.5%$4.09MN/AN/A10
ALBT
Avalon GloboCare
1.0556 of 5 stars		$0.34
-2.6%		N/A-89.5%$4.09M$1.26MN/A5

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ATXI) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel